- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Pelthos outlines mid-2027 XEGLYZE launch timing as ZELSUVMI Q1 net product revenue reaches $10.7M | 1 | Seeking Alpha | ||
| 14.05. | Pelthos Therapeutics Q1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 14.05. | Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates | 1 | Zacks | ||
| 14.05. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Pelthos Therapeutics Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 01.05. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026 | 1 | GlobeNewswire (USA) | ||
| 10.04. | Pelthos Therapeutics ernennt John Gay zum neuen Finanzvorstand | 1 | Investing.com Deutsch | ||
| 10.04. | Pelthos Therapeutics names John Gay as chief financial officer | 1 | Investing.com | ||
| 10.04. | Pelthos Therapeutics names John M. Gay as CFO | 1 | Seeking Alpha | ||
| 10.04. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces CFO Transition | 207 | GlobeNewswire (Europe) | DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet... ► Artikel lesen | |
| 10.04. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Pelthos subsidiary doses first patient in eye pain trial | 2 | Investing.com | ||
| 31.03. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain | 266 | GlobeNewswire (Europe) | First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a... ► Artikel lesen | |
| 19.03. | Oppenheimer raises Pelthos Therapeutics price target to $62 on launch | 1 | Investing.com | ||
| 19.03. | Pelthos signals continued ZELSUVMI momentum and targets expanded product launches through 2027 | 1 | Seeking Alpha | ||
| 19.03. | Pelthos Therapeutics GAAP EPS of -$6.87 misses by $3.84, revenue of $9.39M beats by $0.3M | 1 | Seeking Alpha | ||
| 19.03. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Pelthos Therapeutics Inc. - 10-K, Annual Report | - | SEC Filings |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,265 | +3,03 % | Shortseller-Positionen aktuell: u.a. Deutsche Börse, Evotec, LEG Immobilien, Renk, Symrise, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| VALNEVA | 2,643 | -0,97 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.05.2026 / 17:08 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| CLEARMIND MEDICINE | 3,480 | +42,04 % | Clearmind Medicine Inc.: Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment | Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development... ► Artikel lesen | |
| QIAGEN | 31,645 | +0,43 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,575 | +0,95 % | Bernstein reiterates Summit Therapeutics stock Underperform rating | ||
| RECURSION PHARMACEUTICALS | 3,510 | +2,03 % | Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? | ||
| BIONTECH | 82,50 | +2,87 % | BioNTech SE: BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung | Daten zu Pumitamig aus der laufenden Phase-2/3-Studie ROSETTA Lung-02 bei nicht-kleinzelligem Lungenkrebs in der Erstlinienbehandlung bilden den dritten globalen Studien-Datensatz, der eine ermutigende... ► Artikel lesen | |
| ERASCA | 12,230 | +0,25 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| NUVALENT | 109,23 | -0,04 % | FDA accepts Nuvalent's neladalkib application with priority review | ||
| COGENT BIOSCIENCES | 34,900 | -1,36 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST | NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30... ► Artikel lesen | |
| BEAM THERAPEUTICS | 32,495 | -0,93 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,14 | -2,12 % | H.C. Wainwright reiterates Praxis Precision stock rating on patent news | ||
| DYNE THERAPEUTICS | 19,200 | +3,45 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,72 | -0,13 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 49,420 | -2,79 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report |
PELTHOS THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 25,685 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PELTHOS THERAPEUTICS INC finden Sie auf Wallstreet Online.